Business UpdateJun 3, 2026, 08:31 AM
IN8bio CSO Co-Authors Nature Communications Review on γδ T Cells
AI Summary
IN8bio, Inc. announced the publication of a review article in Nature Communications, co-authored by its Chief Scientific Officer, Lawrence Lamb, Ph.D. The article, titled "Harnessing γδ T cells through engineering and combination therapies," highlights significant advancements in γδ T cell engineering, combination approaches, and clinical development strategies for cancer and autoimmune diseases. This publication underscores the unique biological properties of γδ T cells and their potential to address limitations in current immunotherapy approaches, particularly in difficult-to-treat solid tumors.
Key Highlights
- IN8bio CSO Lawrence Lamb co-authored a review article in Nature Communications.
- The article, "Harnessing γδ T cells through engineering and combination therapies," highlights advances in γδ T cell engineering.
- It discusses combination approaches and clinical development strategies for cancer and autoimmune diseases.
- The review emphasizes γδ T cells' ability to recognize stress-associated signals independent of MHC restriction.
- It highlights the potential for allogeneic "off-the-shelf" γδ T cell therapies.
- IN8bio Scientific Advisory Board member Jonathan Fisher was also a contributing author.
- The publication notes increasing global interest and clinical trials for γδ T cell therapies.
Price Impact
More from INAB